GRAIL, LLC (GRAL) - Total Liabilities
Based on the latest financial reports, GRAIL, LLC (GRAL) has total liabilities worth $301.03 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GRAL long-term investments to assets to see how much of total assets are deployed in long-term investments.
GRAIL, LLC - Total Liabilities Trend (2018–2025)
This chart illustrates how GRAIL, LLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GRAIL, LLC total assets.
GRAIL, LLC Competitors by Total Liabilities
The table below lists competitors of GRAIL, LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
China | CN¥4.15 Billion |
|
Asbury Automotive Group Inc
NYSE:ABG
|
USA | $7.37 Billion |
|
Kenon Holdings
NYSE:KEN
|
USA | $3.08 Billion |
|
Blue Star Limited
NSE:BLUESTARCO
|
India | Rs-34.34 Billion |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
USA | $467.04 Million |
|
SunocoCorp LLC
NYSE:SUNC
|
USA | $21.95 Billion |
|
Adtalem Global Education Inc
NYSE:ATGE
|
USA | $1.24 Billion |
|
Yantai North Andre Juice Co Ltd
SHG:605198
|
China | CN¥182.05 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down GRAIL, LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GRAL equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRAIL, LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRAIL, LLC (2018–2025)
The table below shows the annual total liabilities of GRAIL, LLC from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $344.15 Million | -28.29% |
| 2024-12-31 | $479.90 Million | -47.31% |
| 2023-12-31 | $910.74 Million | -4.73% |
| 2022-12-31 | $955.94 Million | +210.98% |
| 2021-12-31 | $307.40 Million | +112.79% |
| 2020-12-31 | $144.46 Million | +69.97% |
| 2019-12-31 | $84.99 Million | -1.71% |
| 2018-12-31 | $86.47 Million | -- |
About GRAIL, LLC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides deve… Read more